August "earnings season": performance differentiation, structural adjustment... Local enterprises, MNC transformation busy!

In August, major pharmaceutical listed companies have successively released semi-annual reports

"Pharmaceutical Economic News" summarized and analyzed the financial summary of companies with a market value of more than 30 billion yuan in domestic listed pharmaceutical companies in the first half of 2022, and the situation of the secondary market of pharmaceuticals this year can be described as "mud and sand", and the business environment is also facing various tests and pressures

Overall, the performance of most pharmaceutical companies shows an increasing trend, but in the head enterprise segmentation track, the market is beginning to diverge

The strongest revenue capacity of the medical device sector is still the domestic "leader" Mindray Medical, and the total revenue of Mindray Medical in the first half of the year reached 15.

Benefiting from the market increase of epidemic diagnosis products and third-party services, listed companies such as Jiuan Medical, Anxu Biological, Dean Diagnostics, Daan Gene, and Jinyu Medical are still profitable

In the pharmaceutical manufacturing sector, WuXi AppTec, Shanghai Pharmaceutical, Fosun Pharma, Hengrui Pharmaceutical, China Biopharmaceuticals, Baiyunshan, Renfu Pharmaceutical and other leading enterprises, superimposed on the price impact of national collection and medical insurance negotiations, and continued to increase R&D investment, which also brought differentiation to revenue and profits in the first half of the year, and the capital market also gave an emotional response

In terms of biopharmaceuticals, Zhifei Bio has attracted attention with a total revenue of 18.

The following are the details disclosed by each pharmaceutical company:

In addition to the semi-annual reports released by major pharmaceutical companies, in the past August, the pharmaceutical market is still not calm

Multinational pharmaceutical company

Novartis: Divesting sanders from its generics division

Recently, Novartis Group said it plans to divest its generic drug division Sandoz and list it as an independent company on

In response to an interview with the reporter of the New Media Center of Pharmaceutical Economics about novartis' divestiture of Sandoz, Novartis said that the divestiture aims to maximize shareholder value, and will also promote Novartis Innovative Drugs and Sandoz to further focus on their respective businesses and enhance their ability to

Following the spin-off of Sandoz, Novartis will continue to expand its leadership in five core therapeutic areas (hematology, solid tumors, immunology, neuroscience and cardiovascular), its strengths in technology platforms such as gene therapy, cell therapy, radioligand therapy, targeted protein degradation and xRNA, as well as a balanced global presence

AstraZeneca: New Vice President of China, from Novartis

On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of China, head of the Lung Cancer Treatment and Tumor Immunotherapy Related Areas Of the Oncology Division, base in Shanghai, joined the Chinese management team, and reported directly to Chen Kangwei, General Manager of AstraZeneca Oncology Division, effective

Ming Liu has more than 20 years of experience in the pharmaceutical field, before joining AstraZeneca, he was vice president of oncology at Novartis Pharmaceuticals, head of the Solid Tumor Business Unit, responsible for Novartis including breast cancer, lung cancer, melanoma, neuroendocrine tumor rare diseases and other fields

Fresenius Kabi: The Group appoints a new CEO, the President of China and the Chairman of the Board

From August 1, 2022, Yang Weiping will serve as President and Chairman of Fresenius Kabi China, reporting directly to Ulf Jansson

Fresenius Group announced on August 19 that the current CEO of the group, Stephan Sturm, will seek external opportunities; From October 1, Michael Sen, the current CEO of subsidiary Fresenius Kabi, will take over as CEO

Janssen China: Replacement of Compliance Officer of the Medical Compliance Department

On August 22, Zheng Lei, President of Janssen China, announced to employees that Han Jun will join Janssen as the Compliance Officer of Janssen China's Medical Compliance Department, becoming a member of Janssen China's management team, directly reporting to Young Sang Kwon

Local pharmaceutical companies

Cinda Bio: Chief Commercial Officer Liu Min resigned

On August 4, Liu Min, chief commercial officer of Cinda Biotech, will resign due to personal reasons, and will continue to serve as a special consultant for the commercialization of Cinda Biotech for a period of time thereafter, and the heads of subsequent BU will report
directly to Dr.
Yu Dechao, chairman and CEO.
It is reported that Liu Min has more than 20 years of experience in the pharmaceutical industry, and before joining Innovent Biologics, he served as the marketing director of AstraZeneca, the sales director of USSBY, the general manager of Alcon North China, the vice president of Roche Oncology Division and General Pharmaceutical Division
.

Chuangsheng Group: Appointed Executive Vice President and Chief Medical Officer of Global Drug Development

On August 8, Chuangsheng Group announced the appointment of Dr.
Caroline Germa as Executive Vice President and Chief Medical Officer
of Global Drug Development.
Dr.
Germa will be primarily responsible for leading the global development and translational research team to advance the company's pipeline molecules, conducting registered trials, and leading the company's global clinical collaborations
with existing and potential business partners.
Dr.
Germa has over 20 years of industry experience
.
Prior to joining Chuangsheng, he was Vice President of Oncology and Head
of Early Clinical Development at AstraZeneca.

Xinhua Medical: Zhu Qingguo and Wang Jianjian were appointed as deputy general managers

On August 20, Xinhua Medical announced that according to the relevant regulations, the company's meeting deliberated and passed the "Proposal on the Appointment of the Deputy General Manager of the Company", and after the nomination of the general manager of the company, Mr.
Zhu Qingguo and Mr.
Wang Jianjian were appointed as the deputy general managers of the
company.

Among them, Zhu Qingguo has successively served as the chief engineer and deputy director of the company's pharmaceutical equipment factory; Deputy General Manager of Pharmaceutical Equipment Division; Deputy General Manager and General Manager of Pharmaceutical Technology Group; Head of Heze Branch of
Xinhua Medical.
Wang Jianqiang successively served as the chief engineer of the company's infection control equipment factory; Chief Engineer, Deputy General Manager and General Manager
of Infection Control Products Division.

CStone: CEO Jiang Ningjun retires and Yang Jianxin takes over

On August 25, CStone announced a major change
in management at the same time as releasing its 2022 semi-annual report.

Jiang Ningjun, the former CEO of CStone Pharmaceuticals, decided to retire from CStone after leading the development of CStone Pharmaceuticals for 6 years, and in the next period of time, Jiang Ningjun will serve as a senior consultant to the company until the end of this year to ensure a smooth transition
of the company's operations.

Yang Jianxin, Senior Vice President and Chief Medical Officer of the Company, has been appointed as CStone's Chief Executive Officer, Executive Director, Chairman of the Strategy Committee and Authorised Representative with effect
from August 25, 2022.

Genting Shin Yao: Announced the departure of CEO Dr.
Kerui Bo

On 26 August, the Board of Directors of Genting Shin Yao announced that Dr.
Bo has resigned as An executive director and Chief Executive Officer of the Company with effect
from 26 August 2022 in order to devote more time to his personal affairs.
Within 6 months of leaving office, Dr Bo will continue to serve as a consultant
to Genting Shin Yao.
Fu Wei, chairman of Genting Xinyao and CEO of Kangqiao Capital, said that the company has identified the final candidate among the CEO candidates, and the new CEO is expected to take office
within the next month.
In addition, the Board has appointed Genting Shin Yao President and Chief Financial Officer Ying Ho to act as Chief Executive Officer during this period
.

Huiyu Pharmaceutical: The secretary of the board of directors left and hired MaLina as the deputy general manager

On August 26, Huiyu Pharmaceutical issued an announcement on the resignation of the secretary of the board of directors of the company and the appointment of deputy general manager and the appointment of him to act as the secretary of the board of directors, which showed that Ms.
Liu Jingmo, the secretary of the board of directors of the company, resigned
for personal reasons.
On the same day, the Board of Directors of the Company agreed to appoint Ms.
Marina as the Deputy General Manager of the Company for a term of office from the date of deliberation and approval of the Current Board of Directors to the date of expiration of the term of office of the current Board of Directors
.
At the same time, the Board of Directors agreed to appoint Ms.
Marina to act as Secretary of the Board of Directors of the
Company.

According to the information, Ms.
Malina once served as the manager of the general manager office of Beijing Zhaoyan New Drug Research Center, the director of the general manager office/securities department of Shu Taishen (Beijing), the representative of securities affairs, and the directors
, vice presidents and secretaries of the board of directors.

Sichuang Medical Hui: Hired Mr.
Peng Jun as the deputy general manager of the company

On August 30, Sichuang Medical Hui announced that after the nomination of the general manager of the company and the review of the nomination committee of the fifth board of directors of the company, it was agreed to appoint Mr.
Peng Jun as the deputy general manager of the company, and the term of office was from the date of deliberation and approval of the board of directors to the date of expiration of the term of office of the fifth board of directors
.
Mr.
Peng Jun has successively served as an associate researcher of Hangzhou Normal University, an assistant to the general manager of Hangzhou Yinjiang Intelligent Equipment Co.
, Ltd.
, and a director and executive director of many companies
.

Behind the frequent adjustment of executives of major pharmaceutical companies, the changes in the pharmaceutical market continue.
.
.